171 results
8-K
EX-10.1
2pdpx3czycxe
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
S-8
EX-23.1
1nmtsx0apjn0zymgwokb
30 Nov 23
Registration of securities for employees
4:16pm
8-K
81h3gidc8c
14 Nov 23
Other Events
12:00am
8-K
EX-23.1
vdhpvyh
14 Nov 23
Other Events
12:00am
8-K
EX-99.1
sahtg95 7prydkuhwhdl
8 Nov 23
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:37am
8-K
EX-99.1
dtj2y
31 Oct 23
Adaptimmune Reports Positive Data with Lete-cel1 from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
8:07am
8-K/A
06127qad
10 Aug 23
Financial Statements and Exhibits
4:05pm
8-K/A
EX-23.1
mv0d3aw
10 Aug 23
Financial Statements and Exhibits
4:05pm
8-K
EX-99.1
ces yu444a
9 Aug 23
Adaptimmune Reports Second Quarter Financial Results and Business Update
7:42am
8-K
EX-10.1
e9wllon0
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.2
6liwo46umae ugv
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.3
3pu j7m0ttruybumeptl
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
0dqoi1 b8nvgqbed
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm